Illustrative silver-haired man in a teal shirt using an orange resistance band in a bright teal exercise room.

Can You Build Muscle on Ozempic? What Studies Measure

Can you build muscle on Ozempic? Separate actual muscle growth, lean-mass estimates and strength findings, with study limits and clearer care-team questions.

Can you build muscle on Ozempic? The studies commonly cited for this question do not establish a reliable muscle-gain rate or prove that a particular person will gain skeletal muscle while taking it.

First, keep the medications and trials straight

The cited FDA Ozempic injection label identifies semaglutide and type 2 diabetes-related indications; it does not describe a muscle-building treatment. The STEP 1 body-composition analysis tested semaglutide 2.4 mg weekly for weight management in adults without diabetes, not an Ozempic-branded muscle-building program.

The SURMOUNT-1 analysis used tirzepatide; it must not be relabeled as an Ozempic result.

What “build muscle” can mean in the data

Measure What it can tell you What it cannot tell you alone
Scale weight Total body-weight change. Whether the change was fat, water, muscle or other lean tissue.
DXA lean mass Nonfat tissue estimate that can change during weight loss. Exact skeletal-muscle gain or loss; lean mass includes water and other tissues.
Muscle size A direct muscle-focused imaging measure could address growth more closely. It still would not by itself show better strength or daily function.
Strength and function Repeated tests can show whether a person lifts, rises or walks more capably. They do not identify the exact tissue composition of every weight change.

If your goal is muscle gain, ask which outcome will be measured and why. A scan percentage, a training log and daily function answer related but different questions.

What the semaglutide body-composition analysis found

The published 2021 conference abstract of the exploratory STEP 1 DXA analysis included 140 adults without diabetes, with 95 assigned semaglutide and 45 placebo for 68 weeks. In the semaglutide group, total fat mass fell 19.3% and total lean body mass fell 9.7%, while lean tissue became a larger share of the smaller body weight.

These group lean-mass changes do not measure each person’s muscle loss or establish hypertrophy from a particular resistance program.

What the SEMALEAN strength finding adds

The SEMALEAN prospective study enrolled 115 adults with obesity using semaglutide 2.4 mg, and 106 completed 12 months. DXA lean mass fell by the seven-month assessment and then stabilized, while handgrip strength improved.

This observational study separates a grip-test result from a DXA estimate; it does not prove that semaglutide caused improvement, establish hypertrophy or test a randomized muscle-building program.

The paper appeared online in 2025 and in a 2026 journal issue. Its findings should not be generalized automatically to every Ozempic dose, treatment indication, training history or patient.

Why the often-quoted 75/25 split needs a label

In a 160-person SURMOUNT-1 DXA substudy, about 75% of the weight lost was measured as fat and 25% as lean mass in both tirzepatide and placebo groups. Those fractions describe the composition of weight lost, not a 25% loss of starting muscle, and this trial used tirzepatide rather than semaglutide.

Do not use cross-trial percentages as a personal forecast; first record each medicine, group, duration and denominator.

A larger lean-mass percentage can hide a smaller amount

Consider a fictional arithmetic example using abstract units, not patient data. If total weight changes from 100 units to 80 while estimated lean tissue changes from 60 units to 52, the lean share rises from 60% to 65% even though its amount falls.

That example is not a forecast, a body-composition test or a recommendation to lose weight. It shows why an improved percentage and an increase in actual tissue are different statements.

The same discipline applies to strength: a higher test result answers a performance question, while a scan answers a tissue-estimation question. A single headline saying “more muscle” may quietly switch between the two.

Why clinical guidance discusses training and nutrition

The 2025 joint clinical advisory addresses nutritional adequacy, side effects, resistance exercise and muscle health in individualized care. Guidance does not guarantee preservation or growth.

For the exercise-guidance question, see our separate exercise-on-Ozempic discussion. Our GLP-1 muscle-loss evidence review focuses on the risk claim, while this page answers the muscle-gain and measurement question.

A five-question follow-up checklist

  1. What is the aim of my treatment, and which strength or function goal matters most to me?
  2. Am I eating adequately despite appetite or gastrointestinal changes, and would a dietitian assessment help?
  3. Which resistance movements are appropriate for my current health and training history?
  4. If we repeat a body-composition measure, how will we distinguish lean mass from actual muscle and interpret a change?
  5. What changes in strength, daily function or symptoms should prompt a review of the plan?

Do not change or stop prescribed medication based on a scale reading or a generic lean-mass percentage.

Get the next evidence check.

Five practical fitness stories worth your time, every Friday.

One email a week. No product pitches. Unsubscribe in one click.

Sources

Medical disclaimer: This article is general fitness and research information, not medical advice or an individual medication, exercise or nutrition plan. Discuss personal treatment decisions with a qualified clinician or dietitian who knows your health history.

Share your love
Chris Pruitt, certified personal trainer and WorkoutHealthy founder
Chris Pruitt

Chris Pruitt is a certified ASFA personal trainer and the founder of WorkoutHealthy, a fitness equipment retailer serving customers since 2007. He has more than 16 years in the fitness business, and he writes and fact checks everything published on Insider.

The Insider Five

Five stories worth your time, every Friday. One email a week, no pitches.